Actively Recruiting

Phase Not Applicable
Age: 18Years - 99Years
All Genders
NCT06753136

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

Led by Istituto Oncologico Veneto IRCCS · Updated on 2026-04-13

24

Participants Needed

1

Research Sites

240 weeks

Total Duration

On this page

Sponsors

I

Istituto Oncologico Veneto IRCCS

Lead Sponsor

I

IGEA

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneous metastases of different tumor histotypes. Although still limited, the various experiences in the treatment of visceral localizations, particularly in liver metastases from colorectal cancer are promising and show that electrochemotherapy is a safe treatment, even in the case of lesions near large vessels or nerves. The investigators therefore propose a clinical investigation with a Medical Device according to EU Regulation 745/2017, using electrochemotherapy (Cliniporator) with bleomycin for the treatment of visceral, primary or secondary, unresectable localizations, with percutaneous or intraoperative technique (laparoscopic or laparotomy), as needed.

CONDITIONS

Official Title

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

Who Can Participate

Age: 18Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 18 years or older
  • Able to understand and agree to the treatment by signing informed consent
  • Diagnosed with primary or secondary visceral tumors of any histotype
  • Not eligible for standard curative treatments
Not Eligible

You will not qualify if you...

  • Absolute contraindications to invasive procedures
  • Presence of brain, lung, or bone metastases
  • Uncorrectable blood clotting problems
  • Allergy to bleomycin
  • Absolute contraindications to bleomycin
  • Poor lung function or pulmonary fibrosis
  • Acute lung infections
  • Pregnant, breastfeeding, or planning to conceive or father a child during the study period

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Istituto Oncologico Veneto

Padova, Italy, 35128

Actively Recruiting

Loading map...

Research Team

F

Francesco Russano, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here